Ongoing treatment(s)-Chemotherapy - Page 12 of 12 Posts on Medivizor
Navigation Menu

Ongoing treatment(s)-Chemotherapy Posts on Medivizor

Maintenance therapy after bevacizumab and chemotherapy treatment in advanced non–small cell lung cancer patients

Posted by on Aug 4, 2013 in Lung cancer | 0 comments

In a nutshell This phase III trial compared two maintenance therapy strategies in the treatment of advanced non–small cell lung cancer (NSCLC) patients. The effect of bevacizumab (Avastin) was compared to that of combined bevacizumab and pemetrexed (Alimta) treatment. Some background Chemotherapy is one of the main strategies applied in the...

Read More

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR-positive non-small cell lung cancer

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR-positive non-small cell lung cancer

Posted by on Aug 4, 2013 in Lung cancer | 0 comments

In a nutshell This phase III trial compared chemotherapy to erlotinib (Tarceva) as first line treatment for EGFR-positive non-small cell lung cancer (NSCLC) patients. The safety and efficacy of the treatments were compared to decide which treatment is most beneficial for advanced cancer patients. Some background Non-small-cell lung cancer (NSCLC)...

Read More

Evaluating the impact of nerve damage as side effect of chemotherapy in patients with colorectal cancer

Evaluating the impact of nerve damage as side effect of chemotherapy in patients with colorectal cancer

Posted by on Jul 27, 2013 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the frequency and severity of nerve damage (neuropathy) caused by chemotherapy in patients with colorectal cancer. Additionally, researchers evaluated the impact this side effect has on patients’ quality of life. Some background Neuropathy is the damage of nerves caused either by disease or by treatments...

Read More

The effect of cabazitaxel and prednisone in the treatment of metastatic castration resistant prostate cancer

Posted by on Jul 16, 2013 in Prostate cancer | 0 comments

In a nutshell This study looked at the effect, and specifically drug related toxicities, of cabazitaxel (jevtana) plus prednisone treatment in metastatic prostate cancer patients. Some background Prostate cancer grows in response to the hormone testosterone. In order to reduce the effect of testosterone, castration is the mainstay of advanced...

Read More

Evaluating continuation of bevacizumab plus chemotherapy in patients with metastatic colorectal cancer after disease progression

Evaluating continuation of bevacizumab plus chemotherapy in patients with metastatic colorectal cancer after disease progression

Posted by on Jun 27, 2013 in Colorectal cancer | 0 comments

In a nutshell This article evaluated the use of bevacizumab alongside chemotherapy in patients with metastatic colorectal cancer after the progression of the disease following treatment with bevacizumab. Some background Cancer cells need blood supply in order to grow. They do so by forming new blood vessels thereby feeding...

Read More

Risk of Heart Failure after Anthracycline (Adriamycin/Daunomycin) and Trastuzumab (Herceptin) Treatments for Breast Cancer

Risk of Heart Failure after Anthracycline (Adriamycin/Daunomycin) and Trastuzumab (Herceptin) Treatments for Breast Cancer

Posted by on Mar 19, 2013 in Breast cancer | 0 comments

In a nutshell This study evaluated the risk of heart disease associated with two commonly prescribed treatments for breast cancer. The main finding was that Trastuzumab (Herceptin) and Anthracycline (Adriamycin/Daunomycin) treatments are associated with a higher risk of heart failure or ‘cardiomyopathy’. Some background Anthracyclines...

Read More

Benefits of postoperative chemotherapy vary according to breast cancer type

Benefits of postoperative chemotherapy vary according to breast cancer type

Posted by on Feb 25, 2013 in Breast cancer | 0 comments

In a nutshell This study questioned the benefit of adding chemotherapy to postoperative hormonal treatment in the case of lobular breast cancer. Their findings were that chemotherapy seems to offer no additional beneficial effects in women with lobular breast cancer receiving hormonal therapy. Some background There are two main types of breast...

Read More

Risks versus benefit of the ‘HIPEC’ treatment for peritoneal metastases due to colorectal cancer

Risks versus benefit of the ‘HIPEC’ treatment for peritoneal metastases due to colorectal cancer

Posted by on Feb 24, 2013 in Colorectal cancer | 0 comments

Colorectal cancer (CRC) often presents with peritoneal metastases, which have a poor outcome. This means that cancer cells have spread from the colon, appendix, or rectum to the peritoneum (a sheath that covers the abdominal organs). This article argues the pros and cons of a combined treatment for patients with peritoneal metastases from CRC. This...

Read More

Chemotherapy for cancers of the appendix when surgery is not an option

Chemotherapy for cancers of the appendix when surgery is not an option

Posted by on Feb 24, 2013 in Colorectal cancer | 0 comments

In a nutshell This paper assessed the benefits of giving systemic (whole-body) chemotherapy in cancers of the appendix, when surgery combined with intraperitoneal chemotherapy was not an option. Some background Cancers of the appendix are rare, accounting for about 1% of all colon cancers. However, some of these tumors are aggressive and quickly...

Read More